Both in Biotechnology
Protalix BioTherapeutics vs Inhibikase Therapeutics
Over the past year PLX returned +9.2% and IKT returned −7.5%; their daily moves had a correlation of 0.23.
PLX +9.2% IKT −7.5%Growth of $1, one year, split-adjusted
| Metric | PLX | IKT |
|---|---|---|
| Price | $2.61 | $1.48 |
| Market cap | $210.3M | $206.5M |
| Today | +1.95% | −3.90% |
| 1 month | −3.7% | −26.0% |
| 6 months | +33.2% | −23.3% |
| Year to date | +45.0% | −27.8% |
| 1 year | +10.1% | +0.7% |
| Revenue growth (YoY) | +27.1% | — |
| Gross margin | 61.0% | — |
| Net margin | 19.0% | — |
| P/E (TTM) | 11.1× | — |
| Price / sales | 2.6× | — |
| Net cash | $40.7M | $159.0M |
| Dividend yield | — | — |
| Volatility (60d) | 44.8% | 50.9% |
| Short % of float | 4.7% | 17.8% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).